AI Engines For more Details: Perplexity Kagi Labs You
Hypertension: Nilvadipine is effective in lowering blood pressure by relaxing the blood vessels, thus reducing the resistance to blood flow. By dilating the arteries, it allows blood to flow more easily, resulting in decreased blood pressure levels. Controlling hypertension helps reduce the risk of complications such as stroke, heart attack, and kidney problems.
Angina Pectoris: Nilvadipine may be used to manage symptoms of angina pectoris, a condition characterized by chest pain or discomfort due to reduced blood flow to the heart muscle. By dilating the coronary arteries, nilvadipine improves blood flow to the heart, relieving angina symptoms and reducing the frequency of angina attacks.
Vasospastic Angina: Nilvadipine may also be prescribed for the treatment of vasospastic angina (Prinzmetal's angina), a type of angina caused by sudden narrowing or spasms in the coronary arteries. By relaxing the smooth muscle cells in the arterial walls, nilvadipine helps prevent or relieve coronary artery spasms, thereby improving blood flow to the heart.
Chronic Stable Angina: In addition to vasospastic angina, nilvadipine may be used to manage chronic stable angina, a type of angina that occurs predictably during physical exertion or stress. By reducing myocardial oxygen demand and improving coronary blood flow, nilvadipine helps alleviate chest pain and improve exercise tolerance in individuals with chronic stable angina.
Raynaud's Phenomenon: Nilvadipine has been investigated for its potential role in the management of Raynaud's phenomenon, a condition characterized by vasospasm of the small arteries in the fingers and toes, leading to episodes of color changes, numbness, and pain in response to cold or stress. By dilating blood vessels, nilvadipine may help improve blood circulation and reduce the frequency and severity of Raynaud's attacks.
Side Effects: Common side effects of nilvadipine may include dizziness, headache, flushing, swelling of the ankles or feet (peripheral edema), and gastrointestinal symptoms such as nausea and constipation. These side effects are usually mild and transient but may require medical attention if persistent or severe.
Precautions: Nilvadipine should be used with caution in individuals with liver dysfunction, as it is primarily metabolized in the liver. Dose adjustments may be necessary in patients with hepatic impairment to avoid excessive drug accumulation. Additionally, nilvadipine should not be used in pregnant women or nursing mothers unless the potential benefits outweigh the risks.
Drug Interactions: Nilvadipine may interact with other medications, including certain antihypertensive drugs, antifungal agents, antibiotics, and grapefruit juice, leading to increased or decreased plasma concentrations of nilvadipine or other drugs. It is important to consult a healthcare professional or pharmacist before starting or stopping any medications while taking nilvadipine.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 2.6 | 0.3 | 7.67 |
Age-Related Macular Degeneration and Glaucoma | 0.2 | 0.3 | -0.5 |
Allergic Rhinitis (Hay Fever) | 1 | 1 | |
Allergies | 1.6 | 1.9 | -0.19 |
Allergy to milk products | 1 | 0.4 | 1.5 |
Alopecia (Hair Loss) | 0.5 | 0.5 | |
Alzheimer's disease | 1.9 | 4.8 | -1.53 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 0.7 | 1.29 |
Ankylosing spondylitis | 1.9 | 1.1 | 0.73 |
Anorexia Nervosa | 0.3 | 1.6 | -4.33 |
Antiphospholipid syndrome (APS) | 1.5 | 1.5 | |
Asthma | 0 | 0.5 | 0 |
Atherosclerosis | 0.5 | 0.8 | -0.6 |
Atrial fibrillation | 2.1 | 1.7 | 0.24 |
Autism | 5.1 | 5.8 | -0.14 |
Barrett esophagus cancer | 0 | 0 | |
benign prostatic hyperplasia | 0.1 | 0.1 | |
Bipolar Disorder | 1.2 | 0.9 | 0.33 |
Brain Trauma | 0.1 | 0.5 | -4 |
Carcinoma | 1.4 | 1.3 | 0.08 |
Celiac Disease | 1.5 | 1.3 | 0.15 |
Cerebral Palsy | 0.1 | 1 | -9 |
Chronic Fatigue Syndrome | 3 | 3.5 | -0.17 |
Chronic Kidney Disease | 1.9 | 1.6 | 0.19 |
Chronic Lyme | 0.5 | -0.5 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0.6 | -5 |
Chronic Urticaria (Hives) | 0.5 | 1.9 | -2.8 |
Coagulation / Micro clot triggering bacteria | 0.8 | 0.8 | 0 |
Colorectal Cancer | 2.7 | 0.5 | 4.4 |
Constipation | 1.3 | 0.3 | 3.33 |
Coronary artery disease | 1.3 | 0.4 | 2.25 |
COVID-19 | 4.8 | 8.6 | -0.79 |
Crohn's Disease | 4.1 | 3.9 | 0.05 |
cystic fibrosis | 0.4 | 0.5 | -0.25 |
deep vein thrombosis | 0.4 | 0.7 | -0.75 |
Depression | 4.5 | 5.6 | -0.24 |
Dermatomyositis | 0 | 0 | |
Eczema | 0.4 | 1 | -1.5 |
Endometriosis | 1.5 | 0.6 | 1.5 |
Epilepsy | 1.5 | 1.7 | -0.13 |
Fibromyalgia | 1.6 | 2.6 | -0.63 |
Functional constipation / chronic idiopathic constipation | 4.2 | 3.6 | 0.17 |
gallstone disease (gsd) | 1 | 0.2 | 4 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.7 | 0.3 | 4.67 |
Generalized anxiety disorder | 0.9 | 0.6 | 0.5 |
giant cell arteritis | 0 | 0 | |
Glioblastoma | 0 | 0 | |
Gout | 0.3 | -0.3 | |
Graves' disease | 0.6 | 0.4 | 0.5 |
Halitosis | 0.3 | 0 | 0 |
Hashimoto's thyroiditis | 1.4 | 0.3 | 3.67 |
Hidradenitis Suppurativa | 0 | 0 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.7 | 0.9 | 0.89 |
hypercholesterolemia (High Cholesterol) | 0 | 0 | |
hyperglycemia | 0.1 | 0.7 | -6 |
Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | 0 |
hypersomnia | 0.1 | -0.1 | |
hypertension (High Blood Pressure | 1.3 | 2.1 | -0.62 |
Hypothyroidism | 0.4 | -0.4 | |
Hypoxia | 0.6 | 0.6 | |
IgA nephropathy (IgAN) | 3.3 | -3.3 | |
Inflammatory Bowel Disease | 2.1 | 6.5 | -2.1 |
Insomnia | 0.5 | 0.6 | -0.2 |
Intelligence | 1.1 | 1 | 0.1 |
Intracranial aneurysms | 1.2 | 0.1 | 11 |
Irritable Bowel Syndrome | 2.1 | 2.8 | -0.33 |
Liver Cirrhosis | 1.9 | 1.2 | 0.58 |
Long COVID | 4.3 | 4.5 | -0.05 |
Low bone mineral density | 0.6 | -0.6 | |
Lung Cancer | 0.2 | 0.6 | -2 |
ME/CFS with IBS | 0.4 | 1.1 | -1.75 |
ME/CFS without IBS | 0.5 | 0.5 | 0 |
Menopause | 0.4 | 0.4 | |
Metabolic Syndrome | 3.6 | 4.4 | -0.22 |
Mood Disorders | 5.3 | 5.6 | -0.06 |
multiple chemical sensitivity [MCS] | 0.1 | 0.1 | 0 |
Multiple Sclerosis | 1 | 4.6 | -3.6 |
Multiple system atrophy (MSA) | 0.2 | 0.6 | -2 |
Neuropathy (all types) | 0.2 | 0.1 | 1 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.4 | 2.5 | -0.79 |
Obesity | 3.6 | 2.3 | 0.57 |
obsessive-compulsive disorder | 5.2 | 3.3 | 0.58 |
Osteoarthritis | 0.8 | 0.4 | 1 |
Osteoporosis | 0.9 | 0.4 | 1.25 |
pancreatic cancer | 0.1 | 0.1 | |
Parkinson's Disease | 1 | 3.2 | -2.2 |
Polycystic ovary syndrome | 2.1 | 1.1 | 0.91 |
Postural orthostatic tachycardia syndrome | 0 | 0.3 | 0 |
Premenstrual dysphoric disorder | 0.2 | 0.3 | -0.5 |
primary biliary cholangitis | 0.8 | -0.8 | |
Psoriasis | 1.9 | 2.3 | -0.21 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.4 | 1.8 | 0.89 |
Rosacea | 1.3 | 0.2 | 5.5 |
Schizophrenia | 2.3 | 1.1 | 1.09 |
scoliosis | 0.3 | 0.7 | -1.33 |
Sjögren syndrome | 1.6 | 1.9 | -0.19 |
Sleep Apnea | 0.9 | 0.9 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
Stress / posttraumatic stress disorder | 1.1 | 0.8 | 0.38 |
Systemic Lupus Erythematosus | 2.4 | 0.9 | 1.67 |
Tic Disorder | 1.3 | 1.1 | 0.18 |
Tourette syndrome | 0.3 | -0.3 | |
Type 1 Diabetes | 3.4 | 1.2 | 1.83 |
Type 2 Diabetes | 4.4 | 5.1 | -0.16 |
Ulcerative colitis | 1.2 | 4 | -2.33 |
Unhealthy Ageing | 3.8 | 1.5 | 1.53 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.